journal article·2023-08-01Open access

Hyaluronic acid-modified metal–organic framework for two-photon imaging-guided photodynamic therapy in triple negative breast cancer

Ningning Song, Bo Li, Dandan Li, Yunwen Yan

APL Materials· Volume 11· Issue 8

Abstract

Zr-based metal–organic frameworks (MOFs) using thiazolothiazole as an organic ligand exhibit excellent two-photon excited fluorescence performance, particularly in the generation of reactive oxygen species. In this study, a ZrTc nanoMOF was designed and modified with hyaluronic acid (HA) to provide good biocompatibility and cancer cell-specific targeting. In triple negative breast cancer (TNBC), the optimized composite ZrTc@HA exhibited considerable two-photon activity and excellent light-triggered O2·− generation ability at an excitation wavelength of 780 nm. ZrTc@HA can be used as a diagnostic probe for fluorescence imaging and as a therapeutic agent for photodynamic therapy (PDT) with no remarkable toxicity in vitro or in a subcutaneous tumor model in vivo. In summary, we developed a promising two-photon-activated ZrTc@HA for PDT in TNBC, with immense potential for advancements in monotherapy and synergistic phototherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Metal-Organic Frameworks: Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Breast Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University 1 , Hefei 230022, Anhui, People’s Republic of China

Institutes of Physical Science and Information Technology, Key Laboratory of Structure and Functional Regulation of Hybrid Materials, Ministry of Education, Anhui University 2 , Hefei 230601, People’s Republic of China

References (20)

Show source-provided references
1. Nat. Commun. · 2022 · 13 · 657910.1038/s41467-022-34000-6 ↗
2. J. Nanobiotechnol. · 2022 · 20 · 47510.1186/s12951-022-01679-0 ↗
3. Biomater. Res. · 2022 · 26 · 6110.1186/s40824-022-00308-z ↗
4. ACS Appl. Mater. Interfaces · 2022 · 14 · 2959910.1021/acsami.2c05860 ↗
5. Biomater. Adv. · 2022 · 140 · 21304910.1016/j.bioadv.2022.213049 ↗
6. Adv. Mater. · 2019 · 31 · 197003610.1002/adma.201970036 ↗
7. Chem. Soc. Rev. · 2021 · 50 · 508610.1039/d1cs00056j ↗
8. Adv. Sci. · 2022 · 9 · 210391110.1002/advs.202103911 ↗
9. Angew. Chem., Int. Ed. Engl. · 2022 · 61 · e20220675510.1002/anie.202206755 ↗
10. Int. J. Biol. Macromol. · 2020 · 162 · 79810.1016/j.ijbiomac.2020.06.193 ↗
11. Biomolecules · 2021 · 11 · 185010.3390/biom11121850 ↗
12. Front. Oncol. · 2021 · 11 · 68983910.3389/fonc.2021.689839 ↗
13. ACS Appl. Mater. Interfaces · 2021 · 13 · 973910.1021/acsami.1c00583 ↗
14. ACS Appl. Mater. Interfaces · 2023 · 15 · 260210.1021/acsami.2c17691 ↗
15. Pharmacol. Res. · 2023 · 187 · 10663210.1016/j.phrs.2022.106632 ↗
16. Pharmaceutics · 2022 · 14 · 246110.3390/pharmaceutics14112461 ↗
17. Curr. Pharm. Des. · 2020 · 26 · 461510.2174/1381612826666200826140448 ↗
18. Inflammation Regener. · 2022 · 42 · 4010.1186/s41232-022-00226-6 ↗
19. J. Am. Chem. Soc. · 2016 · 138 · 121510.1021/jacs.5b10288 ↗
20. Pharmaceutics · 2022 · 15 · 10910.3390/pharmaceutics15010109 ↗